Phaseline

Companies › Annexin Pharmaceuticals

Annexin Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ANXV
Human recombinant Annexin A5 protein; proposed mechanism involves binding to phosphatidyls
ANXA5Phase 2Non-Proliferative Diabetic Retinopathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07259928ANXVPhase 2Non-Proliferative Diabetic RetinopathyOphthalmologyJul 2026

Targets

ANXA5 (1)

Companies with the same targets

–

Companies built like this

Beacon Therapeutics Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical ONL Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.